[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer * An analysis of a phase 3 trial found that Novo's (NVO [https://seekingalpha.com/symbol/NVO]) experimental CagriSema (cagrilintide and semaglutide) led to an average 25% weight loss in overweight or obese women at week 68. * Just over 2300 women were included in the analysis. * A second analysis [https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=918569] of ~1900 women examined results based on menopausal status.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.